Findings

What do systematic reviews say?

33 questions · 33 findings · 21 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 12.1%GRADE not reported 0 · 0%Very low 4 · 12.1%Low 3 · 9.1%Moderate 8 · 24.2%High 14 · 42.4%

Summary of Findings Table ‐ PBI?APBI vs WBRT

Overall survival · health problem or population

Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).

1 finding from 1 review

Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
HR 0.99 [0.88, 1.12]
8 studies · 13175 participants
High

Intervention not reported

Overall survival · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Overall survival · overweight and obese breast cancer survivors

The review found no eligible studies for this question.

1 finding from 1 review

Body weight management in overweight and obese breast cancer survivors 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Overall survival · women with early breast cancer

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.87 [0.83, 0.92]
27 studies · 39180 participants
High

MBSR vs usual care

Overall survival · women with diagnosed breast cancer

The review found no eligible studies for this question.

1 finding from 1 review

Mindfulness‐based stress reduction for women diagnosed with breast cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Overall survival · adjuvant therapy for early breast cancer

The review found no eligible studies for this question.

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo/observation

Overall survival · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.09]
3 studies · 330 participants
High

Bisphosphonates vs placebo/observation

Overall survival · women with metastatic breast cancer with bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 1.01 [0.91, 1.11]
7 studies · 1935 participants
Moderate

Bisphosphonates vs placebo/observation

Overall survival · women with early breast cancer

Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.91 [0.83, 0.99]
9 studies · 13949 participants
High

Summary of findings: Non‐intensive vs intensive follow‐up

Overall survival · women treated for early breast cancer

Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).

1 finding from 1 review

Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
HR 0.98 [0.84, 1.15]
2 studies · 2563 participants
High

Summary of findings: Decentralised vs centralised follow‐up

Overall survival · women treated for early breast cancer

Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).

1 finding from 1 review

Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
HR 1.07 [0.64, 1.78]
1 study · 968 participants
Moderate

Intervention not reported

Overall survival · women with breast cancer

It is very uncertain whether the intervention changes overall survival (very low certainty).

1 finding from 1 review

Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer 2016 · Cochrane Headline outcomes only
HR 0.72 [0.46, 1.13]
2 studies · 1202 participants
Very low

Intervention not reported

Overall survival · women with breast cancer

It is very uncertain whether the intervention changes overall survival (very low certainty).

1 finding from 1 review

Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer 2016 · Cochrane Headline outcomes only
HR 0.7 [0.28, 1.72]
2 studies · 781 participants
Very low

Intervention not reported

Overall survival · patients with HER2‐positive metastatic breast cancer

The intervention probably leads to lower overall survival (moderate certainty).

1 finding from 1 review

Trastuzumab‐containing regimens for metastatic breast cancer 2014 · Cochrane Headline outcomes only
HR 0.82 [0.71, 0.94]
5 studies · 1309 participants
Moderate

PARPi‐containing regimen vs non‐PARPi regimen

Overall Survival** · locally advanced or metastatic breast cancer

PARPi‐containing regimen showed no clear difference in overall Survival** compared with non‐PARPi regimen (high certainty).

1 finding from 1 review

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes only
HR 0.84 [0.76, 1]
4 studies · 1435 participants
High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Overall survival ( · neoadjuvant therapy for early breast cancer

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

1 finding from 1 review

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.8 [0.6, 1.08]
2 studies · 947 participants
Moderate

Surgery vs primary endocrine therapy

Survival ‐ overall · Women (70 years plus) with operable primary breast cancer

Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).

1 finding from 1 review

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) 2014 · Cochrane Headline outcomes only
HR 0.98 [0.81, 1.2]
3 studies · 495 participants
Low

Surgery plus endocrine therapy vs primary endocrine therapy

Survival ‐ overall · Women (70 years plus) with operable primary breast cancer

Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).

1 finding from 1 review

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) 2014 · Cochrane Headline outcomes only
HR 0.86 [0.73, 1]
3 studies · 1076 participants
Low

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Overall survival (OS) · women with breast cancer and one to three positive lymph nodes

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).

1 finding from 1 review

Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
HR 0.76 [0.6, 0.97]
1 study · 552 participants
Moderate

Platinum vs non‐platinum therapy

Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)

Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
HR 0.85 [0.73, 1]
6 studies · 958 participants
Moderate